EG25227A - Heterocyclic compounds. - Google Patents

Heterocyclic compounds.

Info

Publication number
EG25227A
EG25227A EG50996A EG50996A EG25227A EG 25227 A EG25227 A EG 25227A EG 50996 A EG50996 A EG 50996A EG 50996 A EG50996 A EG 50996A EG 25227 A EG25227 A EG 25227A
Authority
EG
Egypt
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
EG50996A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Roger John Butlin
Roger James
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG25227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of EG25227A publication Critical patent/EG25227A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
EG50996A 1995-06-07 1996-06-06 Heterocyclic compounds. EG25227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
EG25227A true EG25227A (en) 2011-11-17

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
EG50996A EG25227A (en) 1995-06-07 1996-06-06 Heterocyclic compounds.

Country Status (31)

Country Link
US (3) US5866568A (cs)
EP (1) EP0832082B1 (cs)
JP (1) JP3193058B2 (cs)
KR (1) KR100451523B1 (cs)
CN (1) CN1097051C (cs)
AR (1) AR003132A1 (cs)
AT (1) ATE209200T1 (cs)
AU (1) AU715041B2 (cs)
BR (1) BR9608611A (cs)
CA (1) CA2219742C (cs)
CZ (1) CZ289387B6 (cs)
DE (1) DE69617236T2 (cs)
DK (1) DK0832082T3 (cs)
EG (1) EG25227A (cs)
ES (1) ES2168487T3 (cs)
GE (1) GEP20053470B (cs)
HR (1) HRP960272B1 (cs)
HU (1) HUP9802300A3 (cs)
IL (1) IL122464A (cs)
MX (1) MX9709521A (cs)
MY (1) MY114926A (cs)
NO (1) NO314503B1 (cs)
NZ (1) NZ308619A (cs)
PL (1) PL187897B1 (cs)
PT (1) PT832082E (cs)
RU (1) RU2172738C2 (cs)
SK (1) SK282338B6 (cs)
TR (1) TR199701502T1 (cs)
TW (1) TW340845B (cs)
UA (1) UA58494C2 (cs)
WO (1) WO1996040681A1 (cs)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
PL197782B1 (pl) 1999-12-31 2008-04-30 Encysive Pharmaceuticals Inc Sulfonoamidy, środek farmaceutyczny i zastosowanie sulfonoamidów
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
RU2234331C1 (ru) * 2002-12-30 2004-08-20 Смирнов Алексей Владимирович Лекарственное средство
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
ES2337164T3 (es) * 2004-09-21 2010-04-21 Astellas Pharma Inc. Derivados de aminoalcohol.
EP1824861A2 (en) 2004-11-12 2007-08-29 Trustees of the Tufts College Lipase inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
AU2006326649B2 (en) 2005-12-13 2011-03-24 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
CN101437818A (zh) * 2006-03-03 2009-05-20 托伦特药物有限公司 At1和eta受体的新的双重作用受体拮抗剂(dara)
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
DK2094663T3 (da) * 2006-09-21 2011-04-26 Piramal Life Sciences Ltd Pyridin-derivater til behandling af stofskiftesygdomme relateret til insulinresistens eller hyperglykæmi
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
SG174809A1 (en) 2007-05-03 2011-10-28 Intermune Inc Macrocyclic compounds useful as inhibitors of hepatitis c virus
SG182138A1 (en) * 2007-10-12 2012-07-30 Astrazeneca Ab Zibotentan composition containing mannitol and/or microcrystalline cellulose
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
ES2453474T3 (es) * 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
WO2020165226A1 (en) 2019-02-12 2020-08-20 The University Court Of The University Of Glasgow Microvascular angina
WO2021262998A1 (en) * 2020-06-25 2021-12-30 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
CN115803028A (zh) 2020-07-10 2023-03-14 阿斯利康(瑞典)有限公司 用于治疗慢性肾病的齐泊腾坦和达格列净的组合
WO2022270487A1 (ja) * 2021-06-22 2022-12-29 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤及び医薬組成物
AR130179A1 (es) 2022-08-12 2024-11-13 Astrazeneca Ab Terapias combinadas para el tratamiento de la cirrosis con hipertensión portal
TW202446375A (zh) 2023-02-08 2024-12-01 瑞典商阿斯特捷利康公司 用於治療高蛋白尿慢性腎病的齊泊騰坦和達格列淨之組合
WO2025133907A1 (en) 2023-12-18 2025-06-26 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of microvascular angina
WO2025163559A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Combination of zibotentan and dapagliflozin for use for the treatment of hypertension

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
RU2043718C1 (ru) * 1986-01-31 1995-09-20 Исихара Сангио Кайся Лтд. Способ борьбы с нежелательным ростом растений
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
EP0462179A4 (en) * 1989-02-27 1992-03-18 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
TW270116B (cs) * 1991-04-25 1996-02-11 Hoffmann La Roche
WO1992020746A1 (en) * 1991-05-14 1992-11-26 Hybritech, Incorporated Polymeric compositions having bound antibodies
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (cs) * 1992-02-24 1994-06-01 Squibb & Sons Inc
FI944905L (fi) * 1992-04-22 1994-10-19 Warner Lambert Co Endoteliiniantagonistit II
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0650484B1 (en) * 1992-07-17 2000-01-26 Smithkline Beecham Corporation Endothelin receptor antagonists
TW287160B (cs) * 1992-12-10 1996-10-01 Hoffmann La Roche
FI941826L (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
EA007107B1 (ru) * 1995-04-04 2006-06-30 Инсизив Фармасьютикэлз Инк. Тиенил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина

Also Published As

Publication number Publication date
RU2172738C2 (ru) 2001-08-27
SK168097A3 (en) 1998-05-06
KR100451523B1 (ko) 2004-12-03
GEP20053470B (en) 2005-02-25
ATE209200T1 (de) 2001-12-15
DE69617236T2 (de) 2002-07-11
HRP960272A2 (en) 1997-08-31
EP0832082B1 (en) 2001-11-21
JPH11509175A (ja) 1999-08-17
CZ289387B6 (cs) 2002-01-16
NO975700D0 (no) 1997-12-05
AU5840396A (en) 1996-12-30
PL187897B1 (pl) 2004-10-29
UA58494C2 (uk) 2003-08-15
BR9608611A (pt) 1999-05-11
CA2219742A1 (en) 1996-12-19
DK0832082T3 (da) 2002-05-21
HUP9802300A2 (hu) 1999-10-28
US6060475A (en) 2000-05-09
CN1192739A (zh) 1998-09-09
MY114926A (en) 2003-02-28
US6258817B1 (en) 2001-07-10
PL324660A1 (en) 1998-06-08
SK282338B6 (sk) 2002-01-07
PT832082E (pt) 2002-04-29
IL122464A (en) 2002-05-23
MX9709521A (es) 1998-03-31
CN1097051C (zh) 2002-12-25
AU715041B2 (en) 2000-01-13
NO314503B1 (no) 2003-03-31
KR19990022327A (ko) 1999-03-25
DE69617236D1 (de) 2002-01-03
EP0832082A1 (en) 1998-04-01
NZ308619A (en) 2000-01-28
JP3193058B2 (ja) 2001-07-30
CZ388797A3 (cs) 1998-03-18
HRP960272B1 (en) 2006-06-30
CA2219742C (en) 2007-01-16
ES2168487T3 (es) 2002-06-16
WO1996040681A1 (en) 1996-12-19
HUP9802300A3 (en) 2002-02-28
AR003132A1 (es) 1998-07-08
IL122464A0 (en) 1998-09-15
HK1005801A1 (en) 1999-01-29
US5866568A (en) 1999-02-02
TW340845B (en) 1998-09-21
NO975700L (no) 1997-12-05
TR199701502T1 (xx) 1998-03-21

Similar Documents

Publication Publication Date Title
EG25227A (en) Heterocyclic compounds.
ZA965935B (en) Heterocyclic compounds.
EG24195A (en) Heterocyclic compounds
ZA9610020B (en) Heterocyclic compounds
ZA97912B (en) Heterocyclic compounds.
GB9512697D0 (en) Heterocyclic compounds
ZA961444B (en) Pyrazolylbenzoyl derivatives.
GB9518552D0 (en) New heterocyclic compounds
ZA965505B (en) Novel compounds.
PL322722A1 (en) Novel heterocyclic compounds
ZA961449B (en) Isoxazolylbenzoyl derivatives.
GB9504361D0 (en) Heterocyclic compounds
ZA969973B (en) 2-thioxo-imidazolidin-4-one derivatives.
ZA979617B (en) Novel heterocyclic compounds.
ZA967741B (en) Diarylalkenylamine derivatives.
ZA962821B (en) 4-indolylpiperazinyl derivatives.
ZA964560B (en) Anit-viral compounds.
ZA967357B (en) Pyrazol-4-ylbenzoyl derivatives.
PL325637A1 (en) Novel heterocyclic compounds
ZA964034B (en) N-aminopyridone derivatives.
AU1542295A (en) Heterocyclic compounds
ZA962734B (en) Heterocyclic compounds
ZA969560B (en) Substituted 1-methyl-3-phenylpyrazoles.
ZA967934B (en) Heterocyclic compounds.
ZA966126B (en) Heterocyclic compounds.